By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...

Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker estimated ...